Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1573224 | 0.99 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL1573249 | 0.83 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL11638679 | 0.83 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL1038763 | 0.81 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL11792580 | 0.81 | SLC6A4 (0.76) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL5244478 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL11805015 | 0.80 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL11803430 | 0.80 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL5249197 | 0.79 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL1120086 | 0.79 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044067-B2 | Isoquinolines as IGF-1R inhibitors | ANALYTECON S.A. (CH) | 2011-10-25 | — | — | US | disclosed |
| EP-1931636-B1 | ISOQUINOLINES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | ANALYTECON S.A (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099229-A1 | Isoquinolines as IGF-1R Inhibitors | IGF1R, IGFBP1, IGF2BP1 | SLC6A4 3748/4885SLC6A2 3423/4885SLC6A3 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.